SCHEMBL849545

SCHEMBL849545

N#CCc1ccccc1CSC(=N)N

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 11/20 0.57
HTT P42858 5/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
LMNA P02545 3/20 0.57
TAAR1 Q96RJ0 2/20 0.57
HPGD P15428 2/20 0.54
NOS1 P29475 2/20 0.52
NOS3 P29474 1/20 0.52
NOS2 P35228 1/20 0.52
SLC11A2 P49281 2/20 0.49
MAPT P10636 2/20 0.44
TP53 P04637 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
HIF1A Q16665 1/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL851992 0.98 IDO1 (0.58) IDO1HTTSMN1; SMN2LMNATAAR1
SCHEMBL11940555 0.85 HTT (0.58) IDO1HTTSMN1; SMN2LMNATAAR1
SCHEMBL2812696 0.85 IDO1 (0.74) IDO1HTTSMN1; SMN2LMNATAAR1
Bromide SCHEMBL2810146 0.83 IDO1 (0.71) IDO1HTTSMN1; SMN2LMNATAAR1
Hydrochloric Acid SCHEMBL22263112 0.83 IDO1 (0.75) IDO1HTTSMN1; SMN2LMNATAAR1
SCHEMBL11940556 0.80 IDO1 (0.43) IDO1HTTSMN1; SMN2LMNATAAR1
SCHEMBL11940566 0.80 IDO1 (0.43) IDO1HTTSMN1; SMN2LMNATAAR1
SCHEMBL3679465 0.80 IDO1 (0.67) IDO1HTTSMN1; SMN2LMNATAAR1
SCHEMBL11940553 0.79 LMNA (0.47) IDO1HTTSMN1; SMN2LMNATAAR1
SCHEMBL11940573 0.79 LMNA (0.47) IDO1HTTSMN1; SMN2LMNATAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130245062-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2013-09-19 US claimed
US-8338454-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2012-12-25 US claimed
US-20120189537-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION 2012-07-26 US claimed
EP-2432464-A2 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS Cellceutix Corporation (US) 2012-03-28 EP claimed
WO-2010135170-A2 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 WO claimed
US-20100298374-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 US claimed
US-9610275-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2017-04-04 US disclosed
US-9610275-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2017-04-04 US disclosed
US-9610275-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2017-04-04 US disclosed
US-9340491-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2016-05-17 US disclosed
US-9340491-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2016-05-17 US disclosed
US-20130245062-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2013-09-19 US disclosed
US-20130245062-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2013-09-19 US disclosed
US-20120189537-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION 2012-07-26 US disclosed
US-20120189537-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION 2012-07-26 US disclosed
US-20120189537-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION 2012-07-26 US disclosed
US-20100298374-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 US disclosed
WO-2010135170-A2 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 WO disclosed
US-20100298374-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 US disclosed
US-20100298374-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245062-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS NOS1, NOS2, NOS3 IDO1 1551/4885HTT 2947/4885SMN1; SMN2 1107/4885
US-20120189537-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS NOS1, NOS2, NOS3 IDO1 1551/4885HTT 2947/4885SMN1; SMN2 1107/4885
US-20100298374-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS NOS1, NOS2, NOS3 IDO1 1551/4885HTT 2947/4885SMN1; SMN2 1107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.